Volociximab: Encyclopedia with 57,945 entries from biotech, medicine & life sciences.

Life Science Encyclopedia

Volociximab

Volociximab^?
Therapeutic monoclonal antibody
Source	Chimeric
Target	a5b1 integrin
Identifiers
CAS number	?
ATC code	?
PubChem	?
Chemical data
Formula	?
Mol. mass	?
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	?

Volociximab (also known as M200) is a chimeric monoclonal antibody jointly developed by PDL BioPharma and Biogen Idec for treatment of a variety of advanced solid tumors. It binds to and inhibits the functional activity of α5β1 integrin.

v • d • e Chimeric monoclonal antibodies
Cancer immunotherapy	Cetuximab, Rituximab
Other	Abciximab, Basiliximab, Bavituximab, Clenoliximab, Ecromeximab, Galiximab, Gomiliximab, Infliximab, Keliximab, Lumiliximab, Pagibaximab, Teneliximab, Vapaliximab, Volociximab

Categories: Monoclonal antibodies | Cancer treatments

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Volociximab". A list of authors is available in Wikipedia.